At present, FXR agonists are in Phase II and III clinical trials for nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PBC), and primary biliary cirrhosis (PSC)24. Here, NR1H4 is linked to metabolic dysfunction-associated steatotic liver disease.